Muhammad Rizwan Khawaja

Employment

• HonorHealth Research Institute Associate Clinical Investigator, Hematology/Oncology Physician
  2022 - Present
• University of Maryland Upper Chesapeake Health Hematology/Oncology Physician
  2018 - 2022
• Penn State Hershey Cancer Institute Assistant Professor of Medicine
  2017 - 2018
• University of Texas MD Anderson Cancer Center Fellow Physician
  2015 - 2016
• Indiana University School of Medicine Fellow Physician
  2012 - 2015
• Indiana University School of Medicine Resident Physician
  2009 - 2012

Education

• University of Health Sciences MPH
  2008 - 2009
• Aga Khan University MBBS
  2001 - 2006

Projects & Funding

Projects & funding information is unavailable.

Publications (50)

• Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced KRAS-Mutated Metastatic Pancreatic Cancer
  Journal of Immunotherapy and Precision Oncology 2026 DOI: 10.36401/JIPO-25-20
  +Save
• Hodgkin lymphoma patients have an increased incidence of idiopathic acquired aplastic anemia.
  PloS one 2019 DOI: 10.1371/journal.pone.0215021
  +Save
• Multi-Dimensional Analysis of Immune Signature Predicts Response to Decitabine Treatment in Elderly Patients with AML
  Blood 2018 DOI: 10.1182/blood-2018-99-113547
  +Save
• TIGIT Expression Positively Associates with NK Cell Function in AML Patients
  Blood 2018 DOI: 10.1182/blood-2018-99-113578
  +Save
• Short Tandem Repeat Aberrancies in Hematopoietic Stem Cell Transplant Recipients
  The Journal of Molecular Diagnostics 2018 DOI: 10.1016/s1525-1578(18)30401-x
  +Save
• Higher percent recipient chimerism in bone marrow than peripheral blood is risk for relapse
  Human Immunology 2018 DOI: 10.1016/j.humimm.2018.07.034
  +Save
• VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML.
  Oncoimmunology 2018 DOI: 10.1080/2162402x.2018.1469594
  +Save
• Fludarabine/cyclophosphamide (Flu/Cy) non-myeloablative allogeneic stem cell transplant for aplastic anemia and hypoplastic myelodysplasia: A single institution experience.
  Journal of Clinical Oncology 2018 DOI: 10.1200/jco.2018.36.15_suppl.e19021
  +Save
• First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.
  JCI insight 2017 DOI: 10.1172/jci.insight.90380
  +Save
• Adjuvant Gemcitabine and Gemcitabine-based Chemoradiotherapy Versus Gemcitabine Alone After Pancreatic Cancer Resection: The Indiana University Experience.
  American journal of clinical oncology 2017 DOI: 10.1097/coc.0000000000000115
  +Save